From Diabetes Drug to Vision Saver: A New Patent for AMD Eye-Drops

PALM BEACH GARDENS, FL – July 16, 2026 – A common, century-old diabetes drug may be on the verge of a second act, this time as a frontline defense against blindness. Curative Biotechnology, Inc., a development-stage biomedical firm, has secured a pivotal U.S. patent allowance for a topical eye-drop formulation of metformin, aimed at treating degenerative eye diseases like Age-Related Macular Degeneration (AMD).

This intellectual property milestone, announced today, covers the use of metformin eye drops for a range of devastating retinal conditions. For millions suffering from the slow erosion of their sight, it represents a significant step toward a non-invasive treatment in a field currently dominated by uncomfortable and frequent eye injections. The patent not only strengthens Curative's market position but also validates a novel therapeutic strategy licensed from the National Institutes of Health (NIH), potentially shifting the paradigm of retinal care.

The Science of a Second Chance

Metformin is one of the most prescribed drugs globally, known for its ability to manage blood sugar in patients with type 2 diabetes. However, a growing body of scientific evidence suggests its benefits extend far beyond metabolic control. Researchers have discovered the drug possesses powerful anti-inflammatory, antioxidant, and anti-angiogenic (inhibiting abnormal blood vessel growth) properties—all of which are critical in combating the complex pathology of retinal degeneration.

The retina is one of the most metabolically active tissues in the body, and its health is intrinsically linked to cellular energy regulation. Metformin's primary mechanism involves activating a cellular energy sensor called AMPK. In the retina, this activation can help protect cells from stress, reduce inflammation, and preserve the function of the retinal pigment epithelium (RPE)—the very cells that degenerate in diseases like AMD. This scientific rationale forms the bedrock of the technology developed by Dr. Kapil Bharti and his team at the NIH’s National Eye Institute (NEI), which Curative Biotechnology has exclusively licensed.

The true innovation, however, lies in the delivery method. Current leading treatments for AMD, particularly the “wet” form, require regular injections directly into the eye—a daunting and costly prospect for patients. Newer treatments for the “dry” form, or geographic atrophy, have recently been approved but also rely on injections. Curative's patented approach bypasses this entirely, formulating metformin into a topical eye drop. If proven effective, it could offer a painless, at-home alternative that dramatically improves patient comfort and adherence.

"The potential to move from invasive procedures to a simple eye drop is a game-changer for both patients and clinicians," commented one ophthalmology researcher familiar with the challenges of current AMD therapies. "The primary hurdle has always been getting enough of the drug to the back of the eye, so a formulation that achieves this would be a monumental breakthrough."

Building a Biotech on Bedrock IP

For a development-stage company like Curative Biotechnology (OTC: CUBT), this U.S. patent is more than just a scientific validation; it is a cornerstone of its entire corporate strategy. The Notice of Allowance for U.S. Patent Application No. 17/642,610, entitled "Druggable Target to Treat Retinal Degeneration," follows a similar allowance in Canada, creating a strengthening wall of intellectual property around its core ophthalmology platform.

"This U.S. patent allowance represents another important milestone in strengthening our intellectual property portfolio around our metformin-based ophthalmic therapies," said Paul Michaels, Executive Chairman of Curative Biotechnology, in a public statement. He highlighted how this achievement integrates with the company's broader strategy, which includes a recently secured manufacturing agreement with Sterling Pharmaceutical Services to produce clinical supplies and a research collaboration with the University of Pennsylvania's School of Veterinary Medicine to explore veterinary applications.

This methodical assembly of patents, partnerships, and production capabilities is classic biotech strategy for de-risking a novel asset. By licensing the core technology from a prestigious institution like the NEI and enlisting its lead inventor, Dr. Bharti, to its advisory board, Curative has secured a powerful stamp of credibility. This foundation is critical for a small-cap company navigating the high-stakes, capital-intensive world of drug development.

Industry analysts note that building this kind of moat is essential for attracting investment and potential pharmaceutical partners. With a market capitalization hovering around $10 million, Curative is positioning its metformin platform as a well-protected, high-potential asset in a multi-billion-dollar ophthalmology market.

The Path from Patent to Patient

The journey from a patent allowance to a pharmacy shelf is long and arduous, but Curative has a clear roadmap. The next crucial step is a first-in-human clinical study, which is planned to be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI. This collaborative trial will be the ultimate test of the eye-drop's safety and efficacy in humans.

The need for such a trial is underscored by the complex and sometimes contradictory data from existing research. While some large, retrospective studies on diabetic patients have shown that oral metformin use is associated with a lower risk of developing AMD, a recent study published in JAMA Ophthalmology found no such link after adjusting for other factors. This ambiguity highlights the limitations of observational data and reinforces the necessity of a prospective, controlled trial specifically designed to test a topical formulation that delivers the drug directly to the target tissue.

Michaels confirmed the company's multi-faceted approach, stating the patent reinforces their strategy of "advancing a differentiated ophthalmology platform for both human and veterinary applications." This dual-track development could provide earlier revenue streams and additional data to support the human-focused program.

As Curative Biotechnology prepares to take its patented therapy into the clinic, patients and investors will be watching closely. In a world where the standard of care for a leading cause of blindness involves routine eye injections, the prospect of a simple, effective drop offers a powerful new ray of hope.